# A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

> **NCT04806503** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 234 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** UNR844
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04806503
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-06-30
- **Primary completion:** 2022-07-27
- **Final completion:** 2022-10-14
- **Target enrollment:** 234 (ACTUAL)
- **Why stopped:** The study was discontinued by the Sponsor because it did not achieve the primary objective.
- **Last updated:** 2024-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04806503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04806503, "A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04806503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*